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What’s new? 17 
 This study is the first to explore the gut microbiota in patients diagnosed with type 1 18 
diabetes (T1D), but otherwise have excellent glycaemic control and high physical-19 
fitness 20 
 The gut microbiota from the T1D patients with good glycaemic control and high 21 
physical-fitness was comparable to matched non-diabetic healthy controls 22 
  23 
2 
Abstract  24 
Aim: Type 1 diabetes (T1D) is the product of a complex interplay between genetic 25 
susceptibility and exposure to environmental factors. Existing bacterial profiling studies 26 
focus on patients who are most at risk at the time of diagnosis; there is limited data on the gut 27 
microbiota of patients with long standing T1D. This study compared gut microbiota of T1D 28 
patients with good glycaemic control and high levels of physical-fitness with matched non-29 
diabetic controls. 30 
Methods: Ten male type 1 diabetes patients (T1D) and ten matched controls (CON) were 31 
recruited; groups were matched for age, BMI, VO2max, exercise habits. Stool samples were 32 
analysed using next generation sequencing of the 16S rRNA gene to obtain bacterial profiles 33 
from each individual. Phylogenetic investigation of communities by reconstruction of 34 
unobserved states (PICRUSt) was implemented to predict functional content of the bacterial 35 
OTUs.  36 
Results: Faecalibacterium sp., Roseburia sp., and Bacteroides sp. were typically the most 37 
abundant members of the community in both T1D and CON and were present in every 38 
sample in the cohort. Each bacterial profile was relatively individual and no significant 39 
difference was reported between the bacterial profiles or the Shannon diversity indices of 40 
T1D compared with CON. The functional profiles were more conserved and the T1D group 41 
were comparable to that of the CON group. 42 
Conclusions: We show that both gut microbiota and resulting functional bacterial profiles 43 
from patients with longstanding T1D in good glycaemic control and high physical-fitness 44 
levels are comparable to matched non-T1D controls.  45 
3 
Introduction 46 
Type 1 diabetes (T1D) is the product of a complex interplay between genetic susceptibility 47 
and exposure to environmental factors [1]. Environmental exposure has long been implicated 48 
in the pathogenesis of the disease and now, with decades of evidence mapping an increased 49 
rate of incidence, it is clear that disease progression occurs at a rate at which genetic change 50 
alone cannot be solely accountable [2]. 51 
Previous research has shown that the gut microbiota, which is the collection of 52 
microorganisms colonizing the gut, has important roles in the disease [3–5]. Germ-free (GF) 53 
mice models of T1D may acquire the disease at higher rates, but this has been challenged 54 
with no significant differences between GF and colonized mice [6]. In the same study a 55 
Gram-positive organism was isolated which reduced the incidence of the disease. 56 
Administering ‘probiotic’ (live microorganisms which confer health benefits) to mouse 57 
models further demonstrated the potential of intervention targeting the gut microbiota to 58 
reduce disease incidence [6]. Antibiotic administration earlier in life may also predispose 59 
patients to T1D through modulation of the gut microbiota, where certain antibiotic 60 
combinations were recently found to increase diabetes risk [7], although in mice the 61 
incidence was reduced with vancomycin from birth to weaning [8]. 62 
Research in children has shown that the gut microbiota in Finish patients with T1D had 63 
greater Bacterodetes relative to Firmicutes and reduced overall diversity [9]. More recently in 64 
a Spanish cohort patients with T1D had increased abundance of Clostridium, Bacteroides and 65 
Veillonella and reduced abundance of Bifidobacterium and Lactobacillus compared to 66 
controls [10]. Interestingly the latter two organisms are regarded as beneficial and have been 67 
used extensively as probiotic candidates.  Overall these findings indicate that interactions 68 
between the intestinal microbiota and the innate immune system are critical for disease 69 
development [9,11]. However, T1D has a wide spectrum of severity and these studies tend to 70 
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focus on patients at who are most at risk at the time of diagnosis. Thus an important 71 
knowledge gap remains in the literature regarding the status of patients in adulthood with 72 
longstanding diabetes. Moreover, there is limited data examining such individuals who are 73 
intensively managed, demonstrating good glycaemic control and high levels of physical 74 
fitness.  75 
This study seeks to explore gut microbiota in T1D patients with good glycaemic control and 76 
high levels of physical-fitness and matched non-T1D controls. While the gut microbiota 77 
potentially contributes to the T1D onset, we aimed to determine if long-term active suffers 78 
are able to develop a gut microbiome comparable to healthy controls or if important 79 
differences persist long after onset.  80 
5 
Materials and Methods 81 
Participant recruitment and preliminary testing 82 
Fully informed written consent was obtained from all patients following the study’s approval 83 
from National Health Service NRES Committee - Tyne and Wear South. Participants 84 
attended the Newcastle National Institute for Health Research Clinical Research Facility to 85 
establish peak cardio-respiratory parameters during the completion of an incremental-86 
maximal treadmill running protocol as previously described [12]. Participants provided stool 87 
material on tissue paper that was deposited in a sterile falcon tube and stored at -80 ºC until 88 
processing. Tissue paper was sterilised under UV and a negative control sample of toilet 89 
paper was also carried out. 90 
T1D patient eligibility criteria consisted of being aged between 18-35 years, a duration of 91 
diabetes > 5 years, and an HbA1c < 8.0% (64 mmol/mol). In addition, patients were required 92 
to be absent of diabetes-related complications, other than mild-background retinopathy, not 93 
receiving any medication other than insulin (assessed against recent medical notes), and 94 
regularly and consistently undertaking exercise (participating in aerobic based exercise for a 95 
minimum of 30 minutes at a time, at least three times per week). Ten male T1D patients were 96 
recruited (aged 27±2 years, BMI 23.5±0.7 kg.m2, VO2peak 51.3±2.2 ml/kg/min, duration of 97 
diabetes 12±2 years, HbA1c 7.1±0.4% [54.5±2.1 mmol/mol]). Patients were treated with a 98 
basal-bolus regimen composed of long-acting insulins glargine (n = 8) or detemir (n = 2), and 99 
rapid-acting insulin aspart. Eligibility criteria for non-diabetic control participants consisted 100 
of being between 18-35 years, regularly and consistently undertaking exercise. Ten non-101 
diabetic control participants (CON) were recruited (aged 27±2 years, BMI 22.4±0.8 kg/m2, 102 
VO2max 50.9±1.2 ml/kg/min). T1D and CON groups were matched for age, fitness and BMI 103 
(P>0.05). Both groups were habitually consuming a predominantly carbohydrate rich diet 104 
6 
(>60% carbohydrate) assessed via 24 hour recall. Patient demographics are summarised in 105 
Table 1. 106 
 107 
16S rRNA gene bacterial profiling 108 
Participants were provided 3 sections of toilet paper from the same roll that had all undergone 109 
UV sterilisation. Following excrement the participants used the toilet paper once, the soiled 110 
tissue was then collected in sterile universal tubes. Nucleic acid extraction of stool was 111 
carried out on a section of the soiled toilet paper using the PowerLyzer™ PowerSoil® DNA 112 
Isolation Kit (MoBio, CA, USA) in accordance with the manufacturer’s instructions. 113 
Bacterial profiling utilised the 16S rRNA gene targeting variable region 4 and was carried out 114 
by NU-OMICS (Northumbria University) based on the Schloss wet-lab MiSeq SOP and 115 
resulting. raw fastq data were processed using Mothur (version 1.31.2) as described 116 
previously [13]. Briefly, combined reads were trimmed to 275 reads with 0 ambiguous bases. 117 
Chimeric sequences were detected by Chimera.uchime and removed from downstream 118 
analysis. Alignment was generated via the Silva v4 database [14] and Chloroplast, 119 
Mitochondria, unknown, Archaea, and Eukaryota linages were removed from the analysis. In 120 
total, 5,165,964 reads were generated from the 20 samples. Sequences were deposited in MG-121 
RAST under the accession numbers 4603090.3 - 4603109.3. 122 
 123 
Statistical analysis 124 
Data was normalised by subsampling and rarefying all samples to 104,142 reads. The data 125 
was automatically transformed and analysed by principal coordinate analysis (PCA) using 126 
SIMCA 13.0 (Umetrics, Stockholm, Sweden) [15]. The community structure between the 127 
T1D and control groups were analysed by Parsimony and weighted UniFrac analysis [16]. 128 
Significant operational taxonomic unit (OTUs) were classified by the metastats function in 129 
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Mothur using 1000 permutations with multiple hypothesis testing correction [17]. 130 
Phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) 131 
was implemented to predict functional content of the bacterial OTUs [18].   132 
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Results 133 
The number of reads used in the subsampling (104,142) facilitated robust coverage of the gut 134 
microbiota of each individual in the cohort. No significant difference was found between the 135 
T1D and control groups using Parsimony (P = 0.309) and weighted UniFrac (P = 0.107) 136 
Faecalibacterium sp., Roseburia sp., and Bacteroides sp. were typically the most abundant 137 
members of the community in both T1D and CON and were present in every sample in the 138 
cohort (Figure 1). Levels of Bacteroides sp. tended to be higher in CON (P = 0.06) and 139 
Bifidobacterium sp. tended to be higher in T1D (P = 0.08), but neither was significant.  140 
The bacterial profiles of T1D were comparable to the CON group with no distinct clusters 141 
based on the bacterial profiles (Figure 2A). To account for potential false negatives resulting 142 
from some T1D patients with HbA1c outside the range for truly excellent control, further 143 
ordination analysis was conducted by stratifying T1D by HbA1c by > or < 53 mmol/mol. PCA 144 
analysis with this classification showed no distinct clustering based on the overall bacterial 145 
community, with resulting PLS-DA predictive (Q) scores of -0.106 in >53 mmol/mol and 146 
0.022 in <53, where scores of >0.5 represent significant differences and predictively between 147 
the groups (Supplementary Figure 1). Only 17 OTUs from a total of 3,062 were found to be 148 
significantly different between the groups (Table 2). Actinomyces sp. (OTU00428) was the 149 
most significant OTU (P = 0.008) in the T1D group and this was most associated with the 150 
T1D group in the PLS-DA loadings plot (Figure 2B). However, this OTU was detected in all 151 
but 2 patients (both from CON) and only compromised of 62 reads from a total of 2,082,840 152 
(0.003%), where 49 reads were from T1D patients and 13 reads were from CON. No 153 
significant difference (P = 0.344) was found in the Shannon Diversity (H') between each 154 
group. The average T1D H' was 3.37 (range 2.16 – 3.92), whereas the CON H' was 3.13 155 
(range 2.62 – 4.49). 156 
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PICRUSt was implemented to predict functional content of the bacterial OTUs. This showed 157 
that despite the relatively large variation in of the bacterial community between individuals, 158 
the functional profiles were much more comparable (Figure 3). Functional profiles from the 159 
T1D group were comparable to that of the CON group. 160 
10 
Discussion 161 
Alterations in the gut microbiota, whether causative or as a result of T1D, may have 162 
important implications for the health of patients. The aim of the present study was to explore 163 
gut microbiota in T1D patients with good glycaemic control and high levels of physical-164 
fitness against matched non-T1D controls. We show for the first time that intensively 165 
managed T1D patients with optimal glycaemic control and good physical-fitness display 166 
comparable gut microbiota profiles to matched non-T1D individuals. 167 
The gut microbiota profiles were highly individual across the whole cohort, but there is 168 
general conformity between the most dominant members of the community. 169 
Faecalibacterium sp., Roseburia sp., and Bacteroides sp. were found to be the most abundant 170 
in the cohort and generally represented a substantial proportion of the gut microbiota in each 171 
person. These have been previously shown to be prevalent in a healthy adult gut microbiota 172 
[19]. The most significant OTUs driving the separation of the T1D and control gut 173 
communities were generally low in abundance and reflected only a small proportion of the 174 
overall reads. For example the Actinomyces sp. (OTU00428), which was the most significant 175 
OTU in the T1D group, only compromised of 62 reads (49 reads from T1D group) from a 176 
total of 2,082,840 (0.003%). Thus OTUs with such universally low relative abundance are 177 
unlikely to be contributing to disease pathophysiology and implying causality to disease 178 
should be avoided. While the cohort employed in this study is small, 10 T1D patients are 179 
comparable to that of previously published studies and should not influence the lack of 180 
clinically important OTUs discriminating T1D patients and controls [10]. Previous studies 181 
have also inferred associations at diagnosis of increasing Bacteroides and reduced 182 
Bifidobacterium in T1D [9,10]. While these organisms were relatively abundant overall we 183 
see opposing trends, with lower Bacteroides and increased Bifidobacterium in T1D; although 184 
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these differences are noteworthy they were not significant, but further work in a larger cohort 185 
is necessary to confirm these observations. 186 
The Shannon diversity was comparable between T1D and controls with no significant 187 
difference found between the groups. Interestingly, previous studies suggest that children 188 
with T1D undergo dysbiosis of the gut microbiota, resulting in reduced diversity compared to 189 
controls [9,20]. The diversity reported in this study is comparable to that of a non-T1D adult 190 
population, but a lack of published aged-matched controls prevents any comparison with T1D 191 
adults. Nonetheless, the observation that active adults with T1D have a similar diversity to 192 
adults without T1D is important. 193 
Previous studies have suggested an increase of butyrate-producing and mucin-degrading 194 
bacteria in controls, whereas bacteria that produce short chain fatty acids (SCFAs) other than 195 
butyrate were higher in disease cases [21]. Thus synthetic pathways may represent a key 196 
etiological trigger in the onset of T1D. Functional analysis of the bacterial community in this 197 
dataset demonstrated comparability between the bacterial pathways of the OTUs found in 198 
patients with T1D and controls. Despite large variation at the OTU level, the function profiles 199 
showed much greater comparability, as has been previously reported [22]. Noteworthy is that 200 
these functional pathways represent only those of the bacterial community based on the 201 
classification OTUs and thus do not account for differential gene expression between the two 202 
groups. 203 
Given the individual nature of the gut microbiota within each group of the cohort, it is 204 
perhaps not surprising that the ordination analysis of the bacterial profiles showed no distinct 205 
separation of patients with T1D and matched controls. Thus, in adulthood the gut microbiota 206 
is not significantly altered in active patients as a result of being diagnosed with T1D. Notably 207 
this finding was not influenced when T1D patients were further stratified to account for 208 
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ranging HbA1c, with some patients in the T1D groups exhibiting HbA1c outside the range 209 
considered excellent for glycaemic control. Existing comparable data is limited, with studies 210 
to date focusing on differences in the gut microbiota in patients at the time of diagnosis (i.e. 211 
childhood) [9,10]. While the gut microbiota may serve as an environmental trigger in the 212 
onset of T1D in patients where genetic elements alone cannot account for the pathogenesis, 213 
an important finding of this study is that active T1D adults have a gut microbiota reflective of 214 
non-T1D adults. Further work should sample greater numbers of patients temporally and seek 215 
to include sedentary sufferers and those with poorer glycaemic control. Future work should 216 
also consider T1D patients with other pathologies, such as retinopathy or cardiovascular 217 
disease. Considering the lack of available data pertaining to the influence of exercise on gut 218 
microbiota, profiling patients across a range of glycaemic control and physical-activity levels 219 
is warranted to ascertain whether alterations in gut microbiota are influenced by exercise, 220 
glycaemic control, or both, and if intervention or therapeutic manipulation of the gut 221 
microbiota could confer improvements to well-being. The potential influence of differences 222 
in HLA genotype between those with T1D and control participants should also be considered 223 
in future studies. 224 
In summary, this study confirmed existing data relating to the dominant bacterial organisms 225 
in the healthy active adult gut microbiota. Importantly, we show that both gut microbiota and 226 
resulting functional bacterial profiles from patients with longstanding T1D in good glycaemic 227 
control and high physical-fitness levels are comparable to matched non-T1D controls.  228 
13 
COMPETING INTERESTS 229 
None to declare. 230 
 231 
FUNDING 232 
This research was funded by an internal research grant from Northumbria University. 233 
Funders played no part in the study design, in the collection, analysis and interpretation of 234 
data; in the writing of the manuscript; or in the decision to submit the manuscript for 235 
publication. 236 
  237 
14 
References 238 
1.  Knip M, Akerblom HK. Environmental factors in the pathogenesis of type 1 diabetes 239 
mellitus. Exp Clin Endocrinol Diabetes. 1999;107 Suppl S93–100. doi:10.1055/s-240 
0029-1212160 241 
2.  Patterson CC, Gyürüs E, Rosenbauer J, Cinek O, Neu A, Schober E, et al. Trends in 242 
childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-243 
uniformity over time in rates of increase. Diabetologia. 2012;55: 2142–7. 244 
doi:10.1007/s00125-012-2571-8 245 
3.  Stewart CJ, Nelson A, Scribbins D, Marrs ECL, Perry JD, Embleton ND, et al. 246 
Bacterial and fungal viability in the preterm gut: NEC and sepsis. Arch Dis Child Fetal 247 
Neonatal Ed. 2013;98: F298–303. doi:10.1136/archdischild-2012-302119 248 
4.  Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal 249 
microbiome and volatile organic compound metabolome in obese humans with 250 
nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. Elsevier Inc.; 2013;11: 251 
868–875. doi:10.1016/j.cgh.2013.02.015 252 
5.  Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, et al. Gut-associated 253 
bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 254 
2006;55: 1760–1767. doi:10.1136/gut.2005.078824 255 
6.  Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, et al. Oral 256 
probiotic administration induces interleukin-10 production and prevents spontaneous 257 
autoimmune diabetes in the non-obese diabetic mouse. Diabetologia. 2005;48: 1565–258 
75. doi:10.1007/s00125-005-1831-2 259 
7.  Antunes LCM, Han J, Ferreira RBR, Lolić P, Borchers CH, Finlay BB. Effect of 260 
antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother. 261 
2011;55: 1494–503. doi:10.1128/AAC.01664-10 262 
8.  Hansen CHF, Krych L, Nielsen DS, Vogensen FK, Hansen LH, Sørensen SJ, et al. 263 
Early life treatment with vancomycin propagates Akkermansia muciniphila and 264 
reduces diabetes incidence in the NOD mouse. Diabetologia. 2012;55: 2285–94. 265 
doi:10.1007/s00125-012-2564-7 266 
9.  Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, et al. Toward 267 
defining the autoimmune microbiome for type 1 diabetes. ISME J. International 268 
Society for Microbial Ecology; 2011;5: 82–91. doi:10.1038/ismej.2010.92 269 
10.  Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, et al. 270 
Gut microbiota in children with type 1 diabetes differs from that in healthy children: a 271 
case-control study. BMC Med. 2013;11: 46. doi:10.1186/1741-7015-11-46 272 
11.  Atkinson MA, Chervonsky A. Does the gut microbiota have a role in type 1 diabetes? 273 
Early evidence from humans and animal models of the disease. Diabetologia. 2012;55: 274 
2868–77. doi:10.1007/s00125-012-2672-4 275 
15 
12.  Campbell MD, Walker M, Trenell MI, Luzio S, Dunseath G, Tuner D, et al. Metabolic 276 
implications when employing heavy pre- and post-exercise rapid-acting insulin 277 
reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical 278 
trial. PLoS One. 2014;9: e97143. doi:10.1371/journal.pone.0097143 279 
13.  Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a 280 
dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence 281 
data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79: 282 
5112–20. doi:10.1128/AEM.01043-13 283 
14.  Schloss PD, Gevers D, Westcott SL. Reducing the Effects of PCR Amplification and 284 
Sequencing Artifacts on 16S rRNA-Based Studies. PLoS One. Public Library of 285 
Science; 2011;6: e27310. doi:10.1371/journal.pone.0027310 286 
15.  Eriksson L, Johansson E, Kettaneh-Wold N. Multi-and Megavariate Data Analysis, 287 
Part 2, Advanced Applications and Method Extensions. MKS Umetrics AB; 2006. p. 288 
307.  289 
16.  Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R. UniFrac: an effective 290 
distance metric for microbial community comparison. ISME J. Nature Publishing 291 
Group; 2011;5: 169–72. doi:10.1038/ismej.2010.133 292 
17.  White JR, Nagarajan N, Pop M. Statistical methods for detecting differentially 293 
abundant features in clinical metagenomic samples. PLoS Comput Biol. Public Library 294 
of Science; 2009;5: e1000352. doi:10.1371/journal.pcbi.1000352 295 
18.  Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. 296 
Predictive functional profiling of microbial communities using 16S rRNA marker gene 297 
sequences. Nat Biotechnol. Nature Publishing Group, a division of Macmillan 298 
Publishers Limited. All Rights Reserved.; 2013;31: 814–21. doi:10.1038/nbt.2676 299 
19.  Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut 300 
microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464: 301 
59–65. doi:10.1038/nature08821 302 
20.  Kostic AD, Gevers D, Siljander H, Vatanen T, Hyötyläinen T, Hämäläinen A-M, et al. 303 
The Dynamics of the Human Infant Gut Microbiome in Development and in 304 
Progression toward Type 1 Diabetes. Cell Host Microbe. Elsevier; 2015;17: 260–273. 305 
doi:10.1016/j.chom.2015.01.001 306 
21.  Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, et 307 
al. Gut microbiome metagenomics analysis suggests a functional model for the 308 
development of autoimmunity for type 1 diabetes. PLoS One. 2011;6: e25792. 309 
doi:10.1371/journal.pone.0025792 310 
22.  Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Ley RE, Sogin ML, et al. A 311 
core gut microbiom in obese and lean twins. Nature. 2009;457: 480–484. 312 
doi:10.1038/nature07540.A  313 
314 
16 
Table 1 – Individual participant characteristics 
Group 
Patient 
ID 
Age 
(years) BMI 
VO2peak 
(ml/kg/min) 
Fasting Blood 
Glucose 
(mMol/L) 
Diabetes 
Duration 
(years) 
HbA1c 
(mmol/mol) 
Control 
C1 25 22.1 50 4.20 
  
C2 23 21.4 51 4.32 
  
C3 31 21.7 56 4.33 
  
C4 30 20.1 52 3.87 
  
C5 28 26.9 48 3.46 
  
C6 26 21.4 55 4.02 
  
C7 26 23.7 50 3.29 
  
C8 30 25.4 51 4.22 
  
C9 25 21.8 45 4.28 
  
C10 26 20.4 49 4.22 
  
T1D 
T1 29 22.8 57 5.44 5 54 
T2 24 25.9 48 5.75 11 42 
T3 19 22.5 64 5.01 12 49 
T4 34 22.4 50 3.90 5 60 
T5 21 22.5 56 8.43 12 55 
T6 33 27.1 52 7.32 19 58 
T7 29 26.9 41 6.45 5 58 
T8 25 22.8 51 6.31 24 43 
T9 24 22.4 45 3.45 13 50 
T10 31 22.5 46 3.22 19 61 
VO2peak: peak oxygen uptake; BMI: Body mass index. Between group comparisons assessed 
with independent samples t-test. 
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Table 2 – OTUs which differ significantly between T1D and matched controls 
Group P value OTU Phylum Class Order Family Genus 
CON 0.003 Otu00082 Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified 
CON 0.017 Otu01214 Firmicutes Bacilli Bacillales Bacillaceae_1 Anoxybacillus 
CON 0.019 Otu00865 Proteobacteria Alphaproteobacteria Rhizobiales Aurantimonadaceae Aurantimonas 
CON 0.021 Otu00820 Deinococcus-Thermus Deinococci Deinococcales Deinococcaceae Deinococcus 
CON 0.026 Otu00625 Firmicutes Clostridia Clostridiales Clostridiaceae_1 Clostridium_sensu_stricto 
CON 0.027 Otu00217 Firmicutes Clostridia Clostridiales Lachnospiraceae Coprococcus 
CON 0.027 Otu00230 Proteobacteria Betaproteobacteria Burkholderiales unclassified unclassified 
CON 0.032 Otu00807 Proteobacteria Betaproteobacteria Burkholderiales Comamonadaceae Schlegelella 
CON 0.033 Otu01323 Proteobacteria Betaproteobacteria Burkholderiales unclassified unclassified 
CON 0.036 Otu01060 Actinobacteria Actinobacteria Coriobacteriales Coriobacteriaceae unclassified 
CON 0.039 Otu00363 Proteobacteria Betaproteobacteria Rhodocyclales Rhodocyclaceae Zoogloea 
CON 0.041 Otu00384 Proteobacteria Betaproteobacteria Burkholderiales Comamonadaceae unclassified 
T1D 0.008 Otu00428 Actinobacteria Actinobacteria Actinomycetales Actinomycetaceae Actinomyces 
T1D 0.03 Otu00020 Actinobacteria Actinobacteria Coriobacteriales Coriobacteriaceae Collinsella 
T1D 0.03 Otu00021 Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified 
T1D 0.047 Otu00023 Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified 
T1D 0.047 Otu00025 Firmicutes Negativicutes Selenomonadales Veillonellaceae Dialister 
18 
Figure Legends 
 
Figure 1 – Bar Chart of OTUs from type 1 (T1) diabetes and matched controls. Each 
OTU represented as a % of the total community. Patients ordered by Faecalibacterium 
abundance. 
Figure 2 – SIMCA analysis of type 1 (T1) diabetes samples and matched control. A) 
PCA score scatter plot. R2X[1] = 0.124, R2X[2] = 0.0998. B) Loadings Plot showing taxa 
associated with each group. Green (Y) represents each OTU detected, where only the 
significantly different OTUs between cases and control are labelled. Blue (X) shows different 
classification of the model, where OTUs associated with control samples are shown on the 
upper right and OTUs associated with cases are shown on the lower left. 
Figure 3 – Bar Chart of PICRUSt analysis from type 1 diabetes and matched controls. 
Each function represented as a % of the total community. Patients ordered in accordance with 
Figure 1. 
 
Supplementary Figure Legends 
Supplementary Figure 1 – PCA analysis of type 1 diabetes (T) samples and matched 
controls (C), with T1D patients split to account for differing glycaemic control.  T1D 
samples split by HbA1c >53 mmol/mol (orange) and HbA1c <53 mmol/mol with PLS-DA 
scores of -0.106 and 0.022, respectively. 
 
